| abstract |
The invention relates to an aqueous pharmaceutical composition comprising:a) bilastineor a pharmaceutically acceptable salt or solvate thereof,b) mometasone, or a pharmaceutically acceptable derivative thereof,c) a suspending agent, andd) 2-hydroxypropyl-β-cyclodextrin;wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-β-cyclodextrin is less than 8.5% by weight.The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration.The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned. |